12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tafinlar dabrafenib: Interim Phase II data

Interim data from 13 evaluable NSCLC patients with V600 BRAF mutations who failed >=1 line of chemotherapy in the 2-stage, open-label, international Phase II BRF113928 trial showed that twice-daily 150 mg Tafinlar led to an ORR of 54%, including 5 confirmed partial responses, 2 unconfirmed partial responses and 1 case of stable disease. There was 1 discontinuation due to a serious adverse event of hypersensitivity reaction. The most common adverse events reported were decreased appetite, fatigue, asthenia, dyspnea and nausea. Grade...

Read the full 384 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >